GlassScriptPhysician profile
Xiaojun Guo
NPI 1427269257
$2,253.76
in general payments reported to CMS, 2019-2025
25 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $70.27 · 2021: $245 · 2022: $274 · 2023: $303 · 2024: $496 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.23 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.18 | 2023-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $154.62 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $151.66 | 2022 | |
| Amarin Pharma, INC. | $143.91 | 2021-2022 | |
| Amgen INC. | $130.56 | 2025 | Repatha, Otezla |
| Intra-Sana Laboratories | $127.34 | 2023-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Esperion Therapeutics, INC. | $107.25 | 2024-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $103.37 | 2019 | |
| Merck Sharp & Dohme LLC | $100.27 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novo Nordisk INC | $92.32 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $86.34 | 2024-2025 | |
| Lilly USA, LLC | $82.11 | 2024-2025 | Mounjaro |
| Ardelyx, INC. | $69.02 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $66.33 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $63.79 | 2024 | Veozah |
| Exact Sciences Corporation | $45.64 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $45.60 | 2024-2025 | Voquezna |
| Allergan, INC. | $38.53 | 2020 | |
| Aimmune Therapeutics, INC. | $38.48 | 2025 | Zenpep |
| Seqirus USA INC | $33.26 | 2024 | Fluad, Flucelvax |
| Amneal Pharmaceuticals LLC | $24.98 | 2024 | Unithroid |
| Vbi Vaccine (Delaware) INC. | $22.31 | 2023 | Prehevbrio |
| Ibsa Pharma INC. | $20.42 | 2021 | |
| Radius Health, INC. | $19.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaojun Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.